Could a safer sedative shield kidneys during major abdominal surgery?

NCT ID NCT07674719

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial compares two sedatives—remimazolam and propofol—given during liver or pancreas surgery to see which better prevents acute kidney injury after the operation. The study includes adults aged 19 to 85 scheduled for elective hepatobiliary-pancreatic surgery. Researchers aim to find out if remimazolam helps maintain stable blood pressure and reduces kidney damage, especially when fluid intake is limited during surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
remimazolam
What this could lead to
If remimazolam proves better at protecting kidney function, it could become a preferred sedative for surgeries where fluid intake is limited.
What could go wrong
This is a small, early-stage trial with only 78 participants, so results may not apply broadly. Remimazolam may not reduce kidney injury more than propofol.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.